MediciNova announces MN-001 research alliance with Juntendo University

Jun. 23, 2022 1:59 AM ETMediciNova, Inc. (MNOV)By: Meghavi Singh, SA News Editor
  • MediciNova (NASDAQ:MNOV) is up 1.6% after-hours on Wednesday after the firm said that it will initiate a comprehensive research collaboration with Juntendo University, School of Medicine to evaluate the mechanism of the action of MN-001 on lipid metabolism and metabolic syndrome.
  • The lead collaborator is Takashi Mitsui MD, Ph.D., professor and the chair of the Department of Laboratory Medicine, a known leading expert on lipid metabolism who specializes in dyslipidemia and metabolic syndrome.
  • Kazuko Matsuda, MD, Ph.D., MPH, Chief Medical Officer of MediciNova, Inc, commented, "In the phase 2 trial in NASH/NAFLD patients with hypertriglyceridemia, MN-001 (tipelukast) reduced serum triglycerides, increased high-density lipoproteins (HDL-C), and reduced low-density lipoproteins (LDL) during the 12-week treatment period. Furthermore, the improvements in the serum lipid profile were more significant in the patients with type 2 diabetes/prediabetes."

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.